1 Min Read
April 23 (Reuters) - Aclaris Therapeutics Inc:
* ACLARIS THERAPEUTICS ANNOUNCES FIRST PATIENT DOSED IN A PILOT STUDY WITH ATI-502 TOPICAL IN PATIENTS WITH ANDROGENETIC ALOPECIA Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2018 Reuters. All Rights Reserved.